SRPT · Sarepta Therapeutics, Inc.

The thesis

Sarepta Therapeutics' recovery case is still unproven. ELEVIDYS, its Duchenne muscular dystrophy gene therapy, has not shown stabilizing demand, and the third-quarter report on 5 November 2026 is the first hard test. The shares closed at $17.98 on 26 October 2026, 26.5% below the $24.45 52-week high, after a rebound from $16.51 on 13 October 2026.

The rebound came without a new business fact. Piper Sandler kept a Hold rating on 19 October 2026, and TD Cowen kept a Hold rating and a $17 target on 21 October 2026, according to Markets Insider. The narrative is maturing: the story is well known, and the only company items since 13 October 2026 are a preclinical RNA result and the date notice for the quarterly report.

MarketBeat's preview puts third-quarter revenue at $352.20 million against $399.36 million a year earlier. The comparison that matters inside that figure is ELEVIDYS net product revenue against the $98.1 million Sarepta reported for the second quarter.

Bullish and bearish views on Sarepta Therapeutics, Inc.

The bull case on Sarepta Therapeutics, Inc. (SRPT), in brief: Older-patient ELEVIDYS data were positive. The bear case: Revenue is still shrinking.

Bull case

• Older-patient ELEVIDYS data were positive. Sarepta reported on 30 September 2026 that 25 patients dosed at ages 8 to 12 improved on the North Star Ambulatory Assessment by 3.32 points more than 99 external controls over two years (p=0.0022). The company reported no new safety signals.
• Very young patients showed high expression. In the same 30 September 2026 release, six patients aged 2 to 3 in ENDEAVOR Cohort 6 showed mean micro-dystrophin of 93.9% of control by Western blot at week 12.
• The RNA pipeline added preclinical data. Sarepta said on 14 October 2026 that SRP-1003 cut disease-causing RNA in the cell nucleus by up to about 80% in a preclinical myotonic dystrophy model. The program is guided for a second-half 2026 update.
• The second quarter beat estimates. MarketBeat records second-quarter revenue of $401.25 million, reported 5 August 2026, against a $366.39 million estimate, with adjusted earnings of $0.64 a share against $0.22 expected.
• The patent dispute is closed. Sarepta's 23 September 2026 8-K records a $39.0 million settlement with REGENXBIO, which agreed not to sue over existing ELEVIDYS or AAVrh74-based capsids.

Bear case

• Revenue is still shrinking. Second-quarter revenue of $401.25 million was down 34.3% from a year earlier, according to MarketBeat. The same preview expects a further 11.8% year-on-year decline in the third quarter.
• ELEVIDYS is a small part of product sales. Sarepta's second-quarter release lists ELEVIDYS net product revenue of $98.1 million, against $230.6 million from its exon-skipping drugs.
• Analysts remain cautious. RBC Capital cut its target to $17 on 8 October 2026, and TD Cowen kept Hold with a $17 target on 21 October 2026. HC Wainwright reiterated Sell with a $5 target on 5 October 2026, and JPMorgan cut to $20 from $23 on 30 September 2026.
• Ratings lean negative. MarketBeat counted 8 Buy, 7 Hold and 6 Sell ratings on 30 September 2026, with a consensus target of $23.81. That consensus sits above the 26 October 2026 close of $17.98.
• Liver safety limits use. Sarepta's 30 September 2026 release repeats the ELEVIDYS boxed warning for acute serious liver injury and fatal acute liver failure, including fatal cases in non-ambulatory patients.

Price setup

The split- and dividend-adjusted close on 26 October 2026 was $17.98, which is 26.5% below the $24.45 52-week high in the same series. The three-month price change was a gain of 15.7%. The 14-day relative strength index (RSI) was 54.0, a neutral reading; it was 25.9 on 13 October 2026.

On 30 September 2026 MarketBeat listed the 50-day moving average at $18.87 and the 200-day at $18.79. The latest close sits below both of those figures. MarketBeat lists the 52-week low at $14.68, which is 18.4% under the latest close.

Crowding evidence is limited. The shares are not extended above a rising average, and retail-attention measures are not part of the evidence here. The main exposure is the earnings date: the 5 November 2026 report falls ten days after the latest close, and the Street's $17 targets from RBC and TD Cowen bracket the current price.

Catalysts, next 30 days

• By 31 December 2026: Guided window for DM1 and FSHD cohort updates. Neither is dated inside the next 30 days.
• 28 February 2027: FDA action date on traditional approval for AMONDYS 45 and VYONDYS 53. This falls outside the 30-day window and is listed because it decides the exon-skipping franchise.

Elapsed catalysts

• 5 November 2026, after the Nasdaq close: Third-quarter 2026 results, with a call at 4:30 p.m. Eastern. Sarepta announced the date on 22 October 2026. MarketBeat's consensus is $352.20 million in revenue and $0.07 in earnings a share. (passed 1d ago)

What would change the view

The negative read ends if the third-quarter report shows ELEVIDYS net product revenue above the second quarter's $98.1 million, with management describing rising infusion counts. That would be the first evidence that demand has stopped falling. The read deepens if ELEVIDYS revenue falls again, if the FDA issues a new liver-safety communication or label restriction, or if the DM1 and FSHD updates are still unpublished after 31 December 2026.

On price, a daily close below $14.68, the 52-week low listed by MarketBeat, would extend the breakdown. A sustained close above the 50-day and 200-day averages, which MarketBeat put near $18.8 to $18.9 on 30 September 2026, would show the market starting to look through the revenue decline.

What it trades with

Sarepta trades on its own product data and safety news more than on sector moves. On 8 September 2026 the shares fell with a rival's clinical stumble in myotonic dystrophy, so competitor readouts in neuromuscular disease can move the stock.